Evaluating the effectiveness of acid treatment in turnaisian formation of Perm region

The article presents the results of the use of acidic composition of DN-9010 for the stimulation of oil wells in the turnejskih deposits in deposits of Perm region. Authors assessed the impact of technological and geophysical parameters of layers on the success of the acid treatments, by comparing the rates of productivity and production wells before and after acid treatment. When the watercut increases and bottomhole pressure decreases the effectiveness of acid treatment decreases. With the growing volume of acid solution pumped per unit effective oil-acid, performance impact is increasing. Equation for predicting the coefficient obtained productivity wells after the acid treatment

Impact of hydrocarbon drilling mud on mud motor elastomers at different temperatures

The paper describes the experimental research of hydrocarbon drilling mud impact on engineering parameters of mud motor elastomer samples. It is believed to be urgent due to an increase in using mud motors in oil and gas well construction now, and the issue of intense exploitation is currently topical. The test results of elastomer IRP- 1226 dependent on the temperature are shown in the paper. It is proved that the hydrocarbon drilling muds have a significant impact on wearing of mud motors elastomers under the condition of a temperature increase

Characterisation of Recombinant Human Erythropoietin Obtained from CHOpE—Erythropoietin Producing Strain of Chinese Hamster Ovary Cells

Development and implementation in clinical practice of recombinant human erythropoietins (rhEPOs) remain a priority task today. Additional studies were performed in order to obtain clinical trial authorisation for rhEPO tablets for oral use. The studies were aimed to demonstrate the suitability of the erythropoietin producer strain based on Chinese hamster ovary cells (CHOpE) for the production of rhEPO, and the compliance of the substance characteristics with the requirements for erythropoietin (EPO).The aim of the study was to characterise the rhEPO substance obtained from the CHOpE strain cells in accordance with the requirements for EPO.Materials and methods: the rhEPO substance was obtained by culturing the strain of Chinese hamster ovary cells—CHOpE. The expression construct of the producer strain was evaluated using methods for determination of nucleotide and amino acid sequences. The Sanger method was used to perform sequencing of the nucleotide sequence encoding the human EPO gene. The amino acid sequences of the rhEPO molecule C- and N-termini were determined by the Edman method. The copy number of the EPO gene in CHOpE cells was determined by real-time polymerase chain reaction. The properties of the rhEPO substance were evaluated in accordance with the requirements for EPO. Isoelectric focusing, peptide mapping, and polyacrylamide gel electrophoresis were used for identification of the rhEPO substance. The ratio of isoform composition was determined by capillary electrophoresis. Dimer impurities and high molecular weight related substances were determined by high-pressure liquid chromatography. The content of protein and residual nucleic acids was determined by spectrophotometry. The concentration of the rhEPO substance was assessed by enzyme immunoassay.The results of the study confirmed genetic stability of the CHOpE producer strain and demonstrated identity of N- and C-terminal amino acid sequences of the rhEPO molecule to those of the natural EPO. The CHOpE producer strain was used to obtain a rhEPO substance which is homogenous and does not contain impurities of EPO oligomeric forms. Dimers and high molecular weight related substances account for less than 0.5%. The rhEPO molecular weight ranges from 32 to 38 kDa, and the isoelectric point is within 2.8—4.15. The study identified the peaks of isoforms 1–8, the isoform composition of the rhEPO substance corresponds to that of EPO. It was determined that 1 mol of the substance contains 13.75 mols of sialic acids.Conclusions: the study confirmed the suitability of the CHOpE producer strain for the production of rhEPO. The obtained rhEPO substance meets requirements for EPO

Detection of symptom-related coronary arteries in patients with coronary artery disease using real-time three-dimensional stress echocardiography with adenosine triphosphate

Aim 1) To develop normative values of global and regional left ventricular longitudinal deformation (LVLD) during real time three-dimensional stress echocardiography with adenosine triphosphate (ATP) and utilization of automated function imaging technology (4D Stress-Echo + LVLD with ATP); 2) to compare the effectiveness of detection of symptom-related coronary arteries during 4D Stress-Echo with ATP using: a) traditional visual assessment of regional myocardial contractility and b) step-by-step analysis of segmental LVLD.Material and Methods 15 healthy subjects and 32 patients with coronary artery disease (CAD) were examined after coronary angiography. All individuals underwent 4D Stress-Echo + LVLD with ATP (Vivid E95, General Electric).Results The normative values of global LVLD at three stages of the pharmacological stress-test (before, during and after ATP infusion) were –19.5 (95% CI: -20.4 – -19.0), –21.6 (95% CI: -22.8 – -20.4) and –19.5 (95% CI: -20.3 – -18.6), respectively; the values of LVLD in each of the 17 segments of left ventricular myocardium in healthy subjects were also determined. In patients with CAD visual control of contractility during stress test revealed dynamic decrease in local thickening of the myocardium, appearance of new zones of contractility disorders and expansion of previously noted in 31.2% of cases, while analysis of deformation detected the appearance of new zones of deformation disturbances and expansion of previously found – in 68.7% (р = 0.0055). Stress-induced worsening of myocardial deformation during ATP infusion in the zones of blood supply of left anterior descending coronary artery, circumflex artery and right coronary artery (with presence of hemodynamically significant stenoses and occlusions detected during coronary angiography) were found in 28.0, 77.7 and 65.2% respectively (р1-3 = 0.0194; р1-2 = 0.0019; р2-3 = 0.2864).Conclusion The normal values of global and segmental LVLD for each stage of 4D Stress-Echo + LVLD with ATP were determined. 4D Stress-Echo + LVLD with ATP can significantly increase the effectiveness of symptom-related coronary arteries identification in patients with CAD in comparison with traditional Stress-Echo with visual assessment of local myocardial contractility

Practical efficacy and safety of Konsilar D24 in patients with hypertension: data from the KONSONANS program

Aim. In practice, to evaluate the efficacy, safety and long-term adherence to therapy with a fixed-dose combination of ramipril/indapamide (Konsilar-D24) in patients with grade 1-2 hypertension (HTN) who have not achieved blood pressure (BP) control with prior therapy or have not taken antihypertensive therapy.Material and methods. This multicenter open-label observational program included 524 patients with grade 1-2 HTN who did not take antihypertensive therapy or did not reach the target BP level with mono or dual antihypertensive therapy, as well as patients shifted to Konsilar-D24 therapy no later than two weeks before the start of the program. All patients signed a written informed consent to participate in the program. The safety analysis set includes all patients who have taken at least one dose of a fixed-dose combination of ramipril/indapamide and have visited physician at least once during the program. The effectiveness analysis set included all patients in the safety population who completed the study in accordance with protocol (n=511). Clinical systolic blood pressure (SBP), diastolic BP (DBP) and heart rate were assessed at baseline, as well as at 0,5, 1, 3 and 6 months of treatment. A post hoc subgroup analysis of changes in BP and heart rate was performed depending on age, sex and baseline body mass index.Results. The fixed-dose combination of ramipril with indapamide significantly reduced SBP and DBP after 2-week treatment (-20,9±10,1 mm Hg; pConclusion. Despite the limitations inherent in observational studies, the KONSONANS program has demonstrated high efficacy and safety of fixed-dose combination of ramipril/indapamide taken once a day in hypertensive patients. Ramipril/indapamide fixed-dose combination therapy significantly improved BP control and achieved even lower individual target BP levels in the majority of hypertensive patients

Характеризация субстанции рекомбинантного эритропоэтина человека, полученного на основе штамма клеток яичника китайского хомячка CHOpE - продуцента эритропоэтина

Development and implementation in clinical practice of recombinant human erythropoietins (rhEPOs) remain a priority task today. Additional studies were performed in order to obtain clinical trial authorisation for rhEPO tablets for oral use. The studies were aimed to demonstrate the suitability of the erythropoietin producer strain based on Chinese hamster ovary cells (CHOpE) for the production of rhEPO, and the compliance of the substance characteristics with the requirements for erythropoietin (EPO).The aim of the study was to characterise the rhEPO substance obtained from the CHOpE strain cells in accordance with the requirements for EPO.Materials and methods: the rhEPO substance was obtained by culturing the strain of Chinese hamster ovary cells—CHOpE. The expression construct of the producer strain was evaluated using methods for determination of nucleotide and amino acid sequences. The Sanger method was used to perform sequencing of the nucleotide sequence encoding the human EPO gene. The amino acid sequences of the rhEPO molecule C- and N-termini were determined by the Edman method. The copy number of the EPO gene in CHOpE cells was determined by real-time polymerase chain reaction. The properties of the rhEPO substance were evaluated in accordance with the requirements for EPO. Isoelectric focusing, peptide mapping, and polyacrylamide gel electrophoresis were used for identification of the rhEPO substance. The ratio of isoform composition was determined by capillary electrophoresis. Dimer impurities and high molecular weight related substances were determined by high-pressure liquid chromatography. The content of protein and residual nucleic acids was determined by spectrophotometry. The concentration of the rhEPO substance was assessed by enzyme immunoassay.The results of the study confirmed genetic stability of the CHOpE producer strain and demonstrated identity of N- and C-terminal amino acid sequences of the rhEPO molecule to those of the natural EPO. The CHOpE producer strain was used to obtain a rhEPO substance which is homogenous and does not contain impurities of EPO oligomeric forms. Dimers and high molecular weight related substances account for less than 0.5%. The rhEPO molecular weight ranges from 32 to 38 kDa, and the isoelectric point is within 2.8—4.15. The study identified the peaks of isoforms 1–8, the isoform composition of the rhEPO substance corresponds to that of EPO. It was determined that 1 mol of the substance contains 13.75 mols of sialic acids.Conclusions: the study confirmed the suitability of the CHOpE producer strain for the production of rhEPO. The obtained rhEPO substance meets requirements for EPO. Разработка и внедрение в клиническую практику препаратов рекомбинантного эритропоэтина человека (рчЭПО) продолжают оставаться актуальными в настоящее время. Для получения разрешения на проведение клинических исследований таблетированной формы рчЭПО для перорального применения проведены дополнительные исследования для подтверждения пригодности штамма-продуцента CHOpE для производства рчЭПО и соответствия характеристик субстанции требованиям, предъявляемым к ЭПО.Цель работы: характеризация субстанции рчЭПО, полученной на основе клеток штамма продуцента СНОрЕ, в соответствии с требованиями, предъявляемыми к ЭПО.Материалы и методы: субстанцию рчЭПО получали при культивировании штамма клеток яичника китайского хомячка CHOpE. Экспрессирующую конструкцию штамма-продуцента оценивали с помощью методов определения нуклеотидной и аминокислотной последовательностей. Секвенирование нуклеотидной последовательности, кодирующей ген ЭПО человека, проводили по методу Сэнгера. Аминокислотную последовательность С- и N-концов молекулы рчЭПО определяли методом Эдмана. Копийность гена ЭПО в клетках СНОрЕ определяли методом полимеразной цепной реакции в реальном времени. Свойства субстанции рчЭПО изучали в соответствии с требованиями, предъявляемыми к ЭПО. Подлинность субстанции рчЭПО определяли с помощью методов изоэлектрического фокусирования, пептидного картирования и электрофореза в полиакриламидном геле. Для определения соотношения изоформного состава использовали метод капиллярного электрофореза. Для выявления примесей димеров и высокомолекулярных родственных веществ в субстанции применяли метод высокоэффективной жидкостной хроматографии высокого давления. Содержание белка и остаточных нуклеиновых кислот определяли спектрофотометрическим методом. Концентрацию субстанции рчЭПО оценивали методом иммуноферментного анализа.Результаты: подтверждена генетическая стабильность штамма-продуцента СHOpE, доказана идентичность аминокислотной последовательности N- и С-концов молекулы рчЭПО природному ЭПО. На основе штамма-продуцента СHOpE получена субстанция рчЭПО, которая является гомогенной и не содержит примесей олигомерных форм ЭПО. Димеры и высокомолекулярные родственные вещества составляют менее 0,5%. Молекулярная масса рчЭПО находится в диапазоне значений от 32 до 38 кДа, изоэлектрическая точка – от 2,8 до 4,15. Идентифицированы пики изоформ 1–8, изоформный состав субстанции рчЭПО соответствует ЭПО. Установлено, что в 1 моль субстанции содержится 13,75 моль сиаловых кислот.Выводы: подтверждена пригодность штамма-продуцента СНОрЕ для производства рчЭПО. Полученная субстанция рчЭПО соответствует требованиям, предъявляемым к ЭПО

Фокусированная эхокардиография

Background. Transthoracic echocardiography (TTE) is carried out according to expanded protocol. Besides that, focused echocardiography (FOCUS) used is an addition to the physical assessment of cardiac activity in searching for signs or confirming potential diagnosis in specific clinical context. Portable and hand-held imaging devices are used frequently for this aim. FOCUS has not been studied enough in the conditions of domestic health care. Therefore, an objective analysis of the world experience of this method is relevant.Aim: to study the efficiency of FOCUS application using hand-held imaging devices in cardiological practice.Materials and methods. Forty six scientific Englishlanguage publications were analyzed. Text and bibliography are available in the PubMed search system for 2010–2018 years. The use of FOCUS was subjected to critical analysis accordingly to various application fields.Results. A lot of left ventricle structures and functions can be assessed by FOCUS without resorting to TTE or use it for verification later. The method has high diagnostic efficacy in myocardial contractility assessing in patients with acute coronary syndrome. Timely definition of right ventricle size and function might be crucial for clinical suspicion of pulmonary embolism. FOCUS should be used as screening diagnostic method for early detection of valve lesions in rheumatic heart disease.Conclusion. FOCUS is highly informative for various cardiac pathology. It is easy to train in a short time. FOCUS results correlate well with TTE results.Введение. Кроме стационарной трансторакальной эхокардиографии (TTE), которая проводится по развернутому протоколу, существует фокусированная эхокардиография (FOCUS). Этот метод является дополнением физикальной оценки сердечной деятельности для поиска признаков либо подтверждения потенциального диагноза в конкретных клинических ситуациях. Часто при этом используются портативные и карманные устройства для визуализации. Диагностическое значение метода FOCUS в условиях отечественного здравоохранения изучено недостаточно, что делает весьма актуальным объективный анализ мирового опыта его применения.Цель исследования: изучить эффективность применения FOCUS с помощью карманных визуализирующих устройств в кардиологической практике.Материал и методы. Проанализированы 46 научных англоязычных публикаций, текст и библиография которых доступны в поисковой системе PubMed за период 2010 – 2018 гг. Использование метода подвергнуто критическому анализу в соответствии с различными областями его применения.Результаты. Многие структуры и функции левого желудочка можно оценить при помощи FOCUS, не прибегая к методу TTE, либо использовать последний для верификации позже. Метод обладает высокой диагностической эффективностью в оценке кинеза миокарда у пациентов с острым коронарным синдромом. Своевременное определение размера и функции правого желудочка может иметь решающее значение при клиническом подозрении на легочную эмболию. Использовать FOCUS необходимо в качестве скринингового метода диагностики для раннего выявления клапанного поражения при ревматической болезни сердца.Заключение. Метод фокусированной ЭхоКГ является высокоинформативным при различной сердечной патологии. Ему легко обучить в короткие сроки. Результаты FOCUS хорошо коррелируют с результа тами TTE

Measurement of the cross-section and charge asymmetry of WW bosons produced in proton-proton collisions at s=8\sqrt{s}=8 TeV with the ATLAS detector

This paper presents measurements of the $W^+ \rightarrow \mu^+\nu$ and $W^- \rightarrow \mu^-\nu$ cross-sections and the associated charge asymmetry as a function of the absolute pseudorapidity of the decay muon. The data were collected in proton--proton collisions at a centre-of-mass energy of 8 TeV with the ATLAS experiment at the LHC and correspond to a total integrated luminosity of 20.2~\mbox{fb^{-1}}. The precision of the cross-section measurements varies between 0.8% to 1.5% as a function of the pseudorapidity, excluding the 1.9% uncertainty on the integrated luminosity. The charge asymmetry is measured with an uncertainty between 0.002 and 0.003. The results are compared with predictions based on next-to-next-to-leading-order calculations with various parton distribution functions and have the sensitivity to discriminate between them.Comment: 38 pages in total, author list starting page 22, 5 figures, 4 tables, submitted to EPJC. All figures including auxiliary figures are available at https://atlas.web.cern.ch/Atlas/GROUPS/PHYSICS/PAPERS/STDM-2017-13

Measurements of fiducial and differential cross sections for Higgs boson production in the diphoton decay channel at s√=8 TeV with ATLAS

Measurements of fiducial and differential cross sections are presented for Higgs boson production in proton-proton collisions at a centre-of-mass energy of s√=8 TeV. The analysis is performed in the H → γγ decay channel using 20.3 fb−1 of data recorded by the ATLAS experiment at the CERN Large Hadron Collider. The signal is extracted using a fit to the diphoton invariant mass spectrum assuming that the width of the resonance is much smaller than the experimental resolution. The signal yields are corrected for the effects of detector inefficiency and resolution. The pp → H → γγ fiducial cross section is measured to be 43.2 ±9.4(stat.) − 2.9 + 3.2 (syst.) ±1.2(lumi)fb for a Higgs boson of mass 125.4GeV decaying to two isolated photons that have transverse momentum greater than 35% and 25% of the diphoton invariant mass and each with absolute pseudorapidity less than 2.37. Four additional fiducial cross sections and two cross-section limits are presented in phase space regions that test the theoretical modelling of different Higgs boson production mechanisms, or are sensitive to physics beyond the Standard Model. Differential cross sections are also presented, as a function of variables related to the diphoton kinematics and the jet activity produced in the Higgs boson events. The observed spectra are statistically limited but broadly in line with the theoretical expectations

Search for squarks and gluinos in events with isolated leptons, jets and missing transverse momentum at s√=8 TeV with the ATLAS detector

The results of a search for supersymmetry in final states containing at least one isolated lepton (electron or muon), jets and large missing transverse momentum with the ATLAS detector at the Large Hadron Collider are reported. The search is based on proton-proton collision data at a centre-of-mass energy s√=8 TeV collected in 2012, corresponding to an integrated luminosity of 20 fb−1. No significant excess above the Standard Model expectation is observed. Limits are set on supersymmetric particle masses for various supersymmetric models. Depending on the model, the search excludes gluino masses up to 1.32 TeV and squark masses up to 840 GeV. Limits are also set on the parameters of a minimal universal extra dimension model, excluding a compactification radius of 1/R c = 950 GeV for a cut-off scale times radius (ΛR c) of approximately 30